Recent Posts
- Biofortis obtains ANSM authorization and strengthens its position in the development of microbiota-derived therapies
- Launch of a New CME Course on the Gut Microbiome in Immuno-Oncology
- MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis
- MRM Health Raises €55 Million Series B to Advance Best-in-Class Microbiome-Based Biotherapeutic Product Pipeline
- EMIH response to the European Commission call for evidence on the EU Biotech Act
Recent Comments
No comments to show.